SCHEMBL4861398

SCHEMBL4861398

CCOC(=O)COc1ccc(N(C)C(=O)OC(C)(C)C)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.42
ALDH1A1 P00352 3/20 0.40
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.37
MAPK1 P28482 2/20 0.37
CASP3 P42574 1/20 0.37
CASP7 P55210 1/20 0.37
CASP9 P55211 1/20 0.37
USP2 O75604 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PPOX P50336 1/20 0.35
NLRP3 Q96P20 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859381 0.88 ALDH1A1 (0.40) ALDH1A1LMNATSHRMEN1KMT2A
SCHEMBL4861312 0.88 ESR1 (0.52) ESR1ALDH1A1LMNATSHRMAPK1
SCHEMBL4859940 0.87 ESR1 (0.41) ESR1ALDH1A1LMNATSHRMAPK1
SCHEMBL4860564 0.86 ALDH1A1 (0.53) ESR1ALDH1A1TSHRKMT2AGAA
SCHEMBL4860648 0.86 ALDH1A1 (0.46) ESR1ALDH1A1TSHRMAPK1MEN1
SCHEMBL1549489 0.80 ESR1 (0.38) ESR1ALDH1A1TSHRMAPK1CASP3
SCHEMBL1549433 0.78 POLB (0.42) ESR1ALDH1A1LMNATSHRMEN1
SCHEMBL4856543 0.77 ALDH1A1 (0.38) ALDH1A1LMNAMAPK1MEN1KMT2A
SCHEMBL4853470 0.77 LMNA (0.38) ALDH1A1LMNAMEN1KMT2AKDM4E
SCHEMBL4854202 0.77 FFAR1 (0.47) LMNATSHRMAPK1HPGDNLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345067-B2 Aniline derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2008-03-18 US disclosed
EP-1636198-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-22 EP disclosed
WO-2004111020-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-23 WO disclosed
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals PPARA, PPARD, PPARG ESR1 1044/4885ALDH1A1 464/4885LMNA 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.